Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Neema Navai

Showing results (91-100 of 102) with videos related to

Pageof 11
Sort By:
Cell Reports|April 27, 2024
Loss of LPAR6 and CAB39L dysregulates the basal-to-luminal urothelial differentiation program, contributing to bladder carcinogenesisSangkyou Lee, Jolanta Bondaruk, Yishan Wang, et al.
Iscience|June 24, 2022
The origin of bladder cancer from mucosal field effectsJolanta Bondaruk, Roman Jaksik, Ziqiao Wang, et al.
Cancer Research Communications|August 29, 2024
A Pilot Study of the CD38 Antagonist Daratumumab in Patients with Metastatic Renal Cell Carcinoma or Muscle-Invasive Bladder CancerMatthew T Campbell, Amishi Y Shah, Pavlos Msaouel, et al.
Iscience|July 11, 2022
Erratum: The origin of bladder cancer from mucosal field effectsJolanta Bondaruk, Roman Jaksik, Ziqiao Wang, et al.
BJU International|September 24, 2017
Quality of life after brachytherapy or bilateral nerve-sparing robot-assisted radical prostatectomy for prostate cancer: a prospective cohortPierre Blanchard, John W Davis, Steven J Frank, et al.
Nature Genetics|October 15, 2013
Frequent truncating mutations of STAG2 in bladder cancerDavid A Solomon, Jung-Sik Kim, Jolanta Bondaruk, et al.
Cancer|November 20, 2019
Contemporary prostate cancer treatment choices in multidisciplinary clinics referenced to national trendsChad Tang, Karen E Hoffman, Pamela K Allen, et al.
European Urology Oncology|October 13, 2023
Comparative Effectiveness Analysis of Treatment Strategies for Surgically Resectable Neuroendocrine Carcinoma of the Urinary TractOmar Alhalabi, Nathaniel Wilson, Lianchun Xiao, et al.
European Urology|April 23, 2025
Bladder Preservation Strategies in Muscle-invasive Bladder Cancer: Recommendations from the International Bladder Cancer GroupShilpa Gupta, Patrick J Hensley, Roger Li, et al.
Nature Medicine|October 13, 2020
Neoadjuvant PD-L1 plus CTLA-4 blockade in patients with cisplatin-ineligible operable high-risk urothelial carcinomaJianjun Gao, Neema Navai, Omar Alhalabi, et al.
Pageof 11

Showing results (91-100 of 102) with videos related to

Sort By:
Pageof 11
Cell Reports|April 27, 2024
Loss of LPAR6 and CAB39L dysregulates the basal-to-luminal urothelial differentiation program, contributing to bladder carcinogenesisSangkyou Lee, Jolanta Bondaruk, Yishan Wang, et al.
Iscience|June 24, 2022
The origin of bladder cancer from mucosal field effectsJolanta Bondaruk, Roman Jaksik, Ziqiao Wang, et al.
Cancer Research Communications|August 29, 2024
A Pilot Study of the CD38 Antagonist Daratumumab in Patients with Metastatic Renal Cell Carcinoma or Muscle-Invasive Bladder CancerMatthew T Campbell, Amishi Y Shah, Pavlos Msaouel, et al.
Iscience|July 11, 2022
Erratum: The origin of bladder cancer from mucosal field effectsJolanta Bondaruk, Roman Jaksik, Ziqiao Wang, et al.
BJU International|September 24, 2017
Quality of life after brachytherapy or bilateral nerve-sparing robot-assisted radical prostatectomy for prostate cancer: a prospective cohortPierre Blanchard, John W Davis, Steven J Frank, et al.
Nature Genetics|October 15, 2013
Frequent truncating mutations of STAG2 in bladder cancerDavid A Solomon, Jung-Sik Kim, Jolanta Bondaruk, et al.
Cancer|November 20, 2019
Contemporary prostate cancer treatment choices in multidisciplinary clinics referenced to national trendsChad Tang, Karen E Hoffman, Pamela K Allen, et al.
European Urology Oncology|October 13, 2023
Comparative Effectiveness Analysis of Treatment Strategies for Surgically Resectable Neuroendocrine Carcinoma of the Urinary TractOmar Alhalabi, Nathaniel Wilson, Lianchun Xiao, et al.
European Urology|April 23, 2025
Bladder Preservation Strategies in Muscle-invasive Bladder Cancer: Recommendations from the International Bladder Cancer GroupShilpa Gupta, Patrick J Hensley, Roger Li, et al.
Nature Medicine|October 13, 2020
Neoadjuvant PD-L1 plus CTLA-4 blockade in patients with cisplatin-ineligible operable high-risk urothelial carcinomaJianjun Gao, Neema Navai, Omar Alhalabi, et al.
Pageof 11